Attaching multiple ubiquitins (a 76-residue protein ubiquitously expressed in eukaryotic cells) covalently to a protein labels that protein for degradation in the proteasome (a large tunnel-like complex considered as a protein degradation factory). There are many types of ubiquitin ligases (the enzymes that carry out the protein ubiquitination reactions); one of them is the Culin-RING ubiquitin ligase (CRL). There are six Culin proteins and two RING proteins, forming six general types of Culin-RING core platforms for various substraterecruiting subunits to complete the formation of substrate-specific CRLs. The SCF type CRL is formed with Rbx1 (a RING protein), Skp1, Cul1, and an F-box protein. F-box proteins use their F-box sequences to bind Skp1, which, in turn, brings the F-box protein to Cul1. There are about seventy F-box proteins in humans; one of them is Skp2. The name of the specific F-box protein is written in superscript after SCF as in SCF Skp2 . The best-studied substrate of SCF Skp2 is the cyclin-dependent kinase inhibitor p27Kip1. For SCF Skp2 to mediate p27 ubiquitination, p27 must first be phosphorylated on Thr187 (T187) and an auxiliary protein Cks1 must also be present. This reaction therefore can be called the SCF Skp2/Cks1 -p27T187p mechanism; X-ray crystal structure of this complex shows the structural requirement for phosphorylation of p27T187 [1] . In addition to p27, Skp2 has been reported to mediate ubiquitination of about thirty other proteins [2] .
Skp2 knockout mice (Skp2 -/-mice) were generated to determine the physiological roles of Skp2 [3] 
Skp2
-/-mice were found to be resistant to both. Skp2 -/-MEFs were additionally resistant to Ras and E1A. In another study, Skp2 knockout blocked tumorigenesis following loss of the tumor suppressor pRb, but did not inhibit tumorigenesis induced by the chemical carcinogen ENU [6] . Skp2 knockout also did not significantly inhibit Mycdriven lymphomagenesis [7] . Taken together, these findings indicate that Skp2 knockout may not provide a block to tumorigenesis in general. The effects of Skp2 knockout must therefore be experimentally determined for any given type of tumorigenesis. This may prove similar with the specific tumor blocking effects of cyclin D1 knockout [8] .
If Skp2 plays essential tumorigenic roles under specific oncogenic signals, what are the molecular links between a specific oncogenic signal and Skp2? An example is the connection between pRb and Skp2. pRb can inhibit Skp2's ability to ubiquitinate p27 [9] , promote ubiquitination and degradation of Skp2 by the APC ubiquitin ligase [10] , and repress the expression of Skp2 via repressing E2F (since Skp2 is an E2F target gene [11] ). Thus, loss of pRb led to activation of SCF Skp2 activity in mediating p27 ubiquitination. Knockout of Skp2 abolished this effect of pRb loss to block tumorigenesis [6] . Understanding the molecular links between a particular oncogenic signal and Skp2 should reveal more therapeutic targets to interfere with Skp2 activity.
How does Skp2 function when it is found to be required under certain oncogenic signals? Although p27 is a major target of Skp2, Skp2 also targets many other proteins for degradation and Skp2 has non-ubiquitination functions such as binding to cyclin A [12] and p300 [13] . Furthermore, how Skp2 mediates p27 degradation has actually not been clearly delineated since abolishing p27 phosphorylation at Thr187 prevented ubiquitination of the p27T187A mutant (in which Thr187 is changed to Ala, which cannot be phosphorylated) in test tubes but not in p27 T187A/T187A mice [14] . Since there are currently no known mechanisms for Skp2 to mediate ubiquitination of the p27T187A mutant, how Skp2 -/-mice accumulate p27 protein is not clear.
However, p27 T187A/T187A mice were able to block tumorigenesis like Skp2 -/-mice following Rb1 loss, revealing that Skp2 functions in the SCF Skp2/ Cks1 -p27T187p mechanism to promote tumorigenesis following Rb1 loss [6] . It will be important to determine whether p27 T187A/T187A mice are also resistant to tumorigenesis induced by Pten knockout or ARF knockout.
Lin and colleagues revealed an interesting link between Skp2 and Atf4, a transcription factor whose levels often increase during endoplasmic reticulum (ER) stress. Although Atf4 protein levels were increased in Skp2 -/-MEFs with Pten knockout or ARF knockout, the increases did not appear to be due to protein stabilization. Furthermore, other markers of ER stress such as BiP and p-Perk did not increase at the same time. These findings may point to a new direction to study Skp2 function in averting cellular senescence.
Finally, targeting Skp2 to treat cancer has been proposed before, but has now become a more pressing goal with experimental evidence in hand that Skp2 plays essential roles in tumorigenesis -p27T187p should provide a basis for rational design of Skp2-specific inhibitors [1] . Here, a concern is that p27 T187A/T187A mice do not phenocopy Skp2 -/-mice in the regulation of p27 protein levels, except in blocking pituitary tumorigenesis following loss of Rb1. More studies are needed to determine whether p27 T187A/T187A mice could phenocopy Skp2 -/-mice in other types of tumors that could be blocked by Skp2 knockout to identify types of cancers that would potentially be indicated for this treatment strategy. On the other hand, although targeting NAE is not specific for Skp2, it appears to work effectively for the tested tumor cells and is well tolerated by mice. Since many inhibitors that work effectively in labs only to fail spectacularly in clinics, scientists need to continue to explore and discover new ways to treat cancer.
